Concepedia

Masanori Yokono

MY

Statistics

Publications

10

Citations

1.1K

H-Index

10

Active since

2006

Affiliations

Astellas Pharma (Japan)(Current)

Astellas Pharma (Netherlands)

Kissei Pharmaceutical (Japan)

Masanori Yokono is an author at Astellas Pharma (Japan) specializing in pharmacology, medicine, and insulin resistance.

Publications per year

2006–2019

10

Publications

10

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 310 citations

Medicine, Endocrinology, Pharmacology +17

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 194 citations · Full text

Life Sciences, Endocrinology, Pharmacology +10

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono et al. · Journal of Pharmacological Sciences · 2016 · 148 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Journal of Pharmacy and Pharmacology · 2014 · 125 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2011 · 109 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

1–5 of 10